Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig?

In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the det...

Descripción completa

Detalles Bibliográficos
Autor principal: Schmidt, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2020
Materias:
Originalien
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264922/
https://www.ncbi.nlm.nih.gov/pubmed/32837693
http://dx.doi.org/10.1007/s41974-020-00141-z
Descripción
Sumario:In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the detection of mutations in the breast cancer 1 (BRCA1) or BRCA2 gene in the patient’s germline and mutations in the phosphatidylinositol 3 kinase (PI3K) pathway are currently relevant when making decisions regarding targeted therapy.

Ejemplares similares